Pieris Pharmaceuticals is proud to partner with industry leaders in immuno-oncology and respiratory medicines. Read how these key partnerships are helping us produce superior outcomes for patients.
This collaboration combines our leading protein engineering capabilities and unique protein technology with AstraZeneca’s expertise in developing inhaled medicines in respiratory diseases.
Together we will develop up to five drugs, beginning with our leading respiratory asset PRS-060/AZD1402, a first-in-class inhaled IL4Rα antagonist with the potential to treat asthma. We also have the opportunity to co-develop and co-commercialize the program in the U.S., with AstraZeneca retaining the rights to commercialize the drug worldwide.
For the other three programs, we are responsible for initial discovery of novel Anticalin proteins, after which AstraZeneca will lead the continued development. As with PRS-060/AZD1402, we have the option to co-develop and co-commercialize two of these programs in the U.S.
This research collaboration will enable Pieris to combine its robust discovery engine with Genentech’s targets, as well as preclinical and clinical development expertise to create novel therapies for the treatment of respiratory and ophthalmological diseases. These two focus areas of the collaboration are uniquely suited to the advantages offered by the small size of Anticalin proteins when delivered locally. Pieris will be responsible for discovery research and early preclinical development of the programs, and Genentech will be responsible for IND-enabling activities, clinical development, and commercialization of those programs. Genentech will also have the option to select additional targets in return for an option exercise fee. The collaboration does not include any of Pieris’ internal programs.
In partnership with Servier, we are focused on developing PRS-344, a potential best-in-class, PD-L1/4-1BB bispecific. Pieris holds exclusive commercialization rights for PRS-344 in the United States and will receive royalties on ex-U.S. sales by Servier for this program. We are also developing PRS-352, an immuno-oncology bispecific with undisclosed targets.
This collaboration aims to investigate several targeted, bispecific immuno-oncology treatments for solid tumors and blood cancers. Together, we will develop antibody-Anticalin fusion proteins that leverages Pieris’ suite of agonistic costimulatory Anticalin proteins and Seagen’s portfolio of cancer targets and tumor-specific antibodies. The bispecific drugs will be designed to activate a patient’s immune cells locally in the tumor microenvironment.
Boston Pharmaceuticals has exclusively licensed worldwide rights to PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology Anticalin®-antibody bispecific fusion protein. Both parties are collaborating during the investigational new drug (IND)-enabling stage, and Boston Pharmaceuticals is responsible for further development of the program.
